VolitionRx Limited Launches Strategic Public Offering
VolitionRx Limited (NYSE AMERICAN: VNRX) has recently taken a significant step by announcing the pricing of an underwritten public offering. This offering includes 11,550,000 shares of its common stock along with warrants to purchase another 11,550,000 shares of common stock. Each share and the corresponding warrant are priced at $0.52, with $0.01 of that amount allocated to the warrant itself.
Details of the Offering
The public offering will be executed with a striking element: each warrant has an exercise price of $0.60, is immediately exercisable upon issuance, and will expire five years from the date it is issued. Furthermore, the company is allowing underwriters a 30-day option to buy up to an additional 1,732,500 shares along with related warrants, which provides flexibility in addressing potential over-allotments associated with the offering.
Without the exercise of the underwriter's option, the gross proceeds expected from this offering are about $6.0 million. Should the warrants be fully exercised, the Company could see additional proceeds rise to approximately $6.9 million. However, there is no guarantee on warrant exercises, which adds a layer of uncertainty to the financial projections.
Use of Proceeds
VolitionRx has outlined that the net proceeds from this offering will primarily be allocated toward research and continued product development, clinical studies, and other organizational financing needs. The funds will ensure ongoing commercialization efforts, working capital, and may also support potential strategic acquisitions to further enhance the company's capabilities.
Role of Underwriters
In this offering, Newbridge Securities Corporation is acting as the exclusive book-running manager, supporting Volition in navigating the complexities of this financial endeavor. This partnership aims to streamline the process and maximize the resources available to Volition.
All available securities are offered under a “shelf” registration statement, which was filed with the Securities and Exchange Commission (SEC) and has undergone amendments and effectiveness confirmations. This structure enables efficient capital raises in compliance with regulatory standards, ensuring transparency and investor confidence.
The Volition Commitment
VolitionRx is dedicated to advancing the intricate field of epigenetics with a focus on life-saving innovations. The Company’s primary mission revolves around improving health outcomes by facilitating earlier detection of diseases and enhancing monitoring capabilities through accessible blood tests.
Through continuous investment in research, Volition is committed to developing affordable, user-friendly blood tests capable of detecting a variety of conditions, including specific cancers and diseases linked with NETosis, such as sepsis. These advancements are poised to not only enhance longevity but also significantly enrich the quality of patient life.
A Focus on Innovation
Headquartered in a multi-national environment, with key research and development facilities in Belgium and innovation labs in the U.S. and London, Volition is strongly positioned at the forefront of scientific discovery in epigenetics. This global network enables the company to leverage expertise and resources to further its objectives.
Volition continues to work vigorously on its initiatives, aiming to make a notable impact in healthcare by integrating advanced science into real-world applications.
Frequently Asked Questions
What is the purpose of VolitionRx's public offering?
The public offering aims to generate funds for research, clinical studies, and other corporate purposes to enhance product development and commercialization efforts.
How much is VolitionRx looking to raise through this offering?
VolitionRx expects to raise approximately $6.0 million in gross proceeds before deductions, with the possibility of an additional $6.9 million from warrant exercises.
Who is managing the public offering?
The offering is being managed solely by Newbridge Securities Corporation, which will facilitate the execution of this initiative.
What types of diseases is VolitionRx focused on detecting?
VolitionRx develops blood tests aimed at detecting various conditions, emphasizing cancers and diseases associated with NETosis, such as sepsis.
Where are Volition's research facilities located?
VolitionRx operates its research facilities primarily in Belgium, with additional innovation laboratories and offices in the U.S. and London.
